• LAST PRICE
    0.0000
  • TODAY'S CHANGE (%)
    Trending Down0.0000 (-90.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0000
  • Day Range
    Low 0.0000
    High 0.0000
  • 52 Week Range
    Low 0.0000
    High 0.0755
  • Volume
    3,050
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1E-06
TimeVolumeCRXM
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCRXM
Gene Biotherapeutics Inc
60.0
0.0x
---
United StatesTNGNQ
Tengion Inc
40.0
0.0x
---
United StatesSNNAQ
Sienna Biopharmaceuticals Inc
30.0
0.0x
---
United StatesOVIT
Oncovista Innovative Therapies Inc
20.0
0.0x
---
United StatesVIAP
VIA Pharmaceuticals Inc
20.0
0.0x
---
United StatesNTME
Netmed Inc
1.4K
0.0x
---
As of 2022-01-22

Company Information

Gene Biotherapeutics Inc. is a clinical stage biotechnology company. The Company is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for primarily for the treatment of cardiovascular disease. The Company’s technology platform is designed to biologically activate the human body’s innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Generx has been cleared Phase III clinical study, the AFFIRM study.

Contact Information

Headquarters
11750 Sorrento Valley Rd Ste 250SAN DIEGO, CA, United States 92121-1061
Phone
858-436-1000
Fax
858-436-1001

Executives

Chairman of the Board, Chief Financial Officer, Secretary
James Grainer
President, Chief Executive Officer, Treasurer
Christopher Reinhard
Chief Operating Officer
Lois Chandler
Chief Scientific Officer
Ronald Shebuski
Director
Kaushik Vyas

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$60.00
Revenue (TTM)
$0.00
Shares Outstanding
64.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
3.86
EPS
$0.08
Book Value
$-0.30
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.